NEWS

San Jose, CA – April 1, 2023 (PRESS RELEASE)

Biomed Industries, Inc. ™ Inc. (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”)

Biomed Industries, Inc. (Biomed) introduced a new approach and presented results of its Phase 2A clinical trial of NA-831 for the treatment of Alzheimer’s Disease (AD) at the Alzheimer's Disease/Parkinson's Disease International Conference, March 28- April 1, 2023 in Gothenburg, Sweden.

The absence of disease-modifying drug treatments for Alzheimer’s Disease (AD) today can be attributed to the yet unproven Amyloid Cascade Hypothesis, which has dominated drug discovery and clinical development in AD for 30 years. Almost all Alzheimer drug candidates based on the Amyloid Hypothesis have failed.

At the AD/PD 2023, Biomed introduced the Neurogenesis Hypothesis as a potential replacement of the Amyloid Hypothesis. The Company also presented the Phase 2A clinical data of its new drug, NA-831, which can be taken orally for the treatment of Alzheimer’s Disease. NA-831 is based on the guidance of the Neurogenesis Hypothesis.

The hippocampus, a brain area critical for learning and memory, contains neural progenitor cells (NPCs) that continue to generate new neurons throughout life, a process known as adult hippocampal neurogenesis (AHN). Hippocampal neurogenesis is persistent through the tenth decade of human life and is detectable in patients with Alzheimer’s disease (AD).

AHN impairment compromises hippocampal function and appears to take place prior to the presence of senile plaques and neurofibrillary tangles (NFTs), both of which are key pathological hallmarks of AD. Most currently approved AD drugs target these plaques and, unfortunately, have not shown clinical benefit in treating the disease as yet. As a consequence, they have not been approved for reimbursement by the Center for Medicaid and Medicare Services (Medicare).

In a recent article entitled "The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?", published in the journal Biomolecules, Kurkinen and colleagues concluded that for Eisai’s lecanemab, the “claimed figure of 27% slowed cognitive decline was misleading. The actual figure was only 9.3% and it was unlikely to provide clinically meaningful benefit in people living with mild to moderate Alzheimer’s disease.”

NA-831 was found to easily cross the Blood-brain barrier and serve as a catalyst to restore neurogenesis and generate new neurons in the hippocampus in Alzheimer’s patients, leading to improved cognitive function.

With the completion of the Phase 2A clinical trial, which showed a significant improvement for patients with MCI, and mild to moderate Alzheimer’s disease as measured by ADAS Cog 13 after 24 weeks, Biomed is launching Phase 3 trials in the USA and a number of countries around the world.

“With the long history of drugs targeting Amyloid Beta in the treatment of AD showing no real clinical benefit, the time to more broadly explore and rapidly expand the Neurogenesis hypotheses has come”, said Lloyd L. Tran, Chairman and CEO of Biomed. He continued: ”We believe that our Neurogenesis drug, NA-831, acting alone or in conjunction with drugs from Biogen, Eisai, Eli Lily, and others, is an exciting new pathway for the treatment of Alzheimer’s Disease. Working with the JP Morgan M&A team enables us to form strategic partnerships with major pharmaceutical companies to bring NA-831 to the global market.”

About Biomed Industries, Inc.

Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer’s disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com

- CONTACT:

Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com